(May 25, 2016) A new study published in the International Journal of Gynecological Cancer earlier this month investigated the impact of body mass index (BMI) on completion, complications, and clinical outcomes of intraperitoneal (IP) chemotherapy in patients with advanced-stage ovarian cancer.
The study followed ninety two patients through a minimum of one cycle of IP chemotherapy and a maximum of 6 cycles. They found that one’s BMI did not have a significant impact on complications or overall survival rate when using IP chemotherapy. Those with class II obesity, or extreme obesity, did show a trend away from treatment with IP therapy in extreme obesity. Overall, these data suggest that IP chemotherapy is feasible in obese patients without incurring increased morbidity.
To read the article abstract click here.
